Clinical Assessment: Likely Continued Benefit with Close Monitoring Required
This patient appears to be deriving continued clinical benefit from BMS-986460, though the recent 19% PSA rise warrants heightened surveillance for emerging resistance. The totality of evidence—improving hemoglobin, stable performance markers, normal LDH, and castrate testosterone—suggests ongoing disease control despite the single-month PSA increase.
Evidence Supporting Continued Benefit
Favorable Laboratory Trends
The patient demonstrates multiple indicators of disease stability that outweigh the isolated PSA fluctuation:
- Progressive hemoglobin improvement: 11.9 → 13.1 g/dL over five months indicates absence of bone marrow compromise from progressive disease
- Normal and stable LDH (144 U/L, reference <248): Remains well below the upper limit despite modest increase from 120, arguing against aggressive disease progression 1
- Maintained castrate testosterone: Consistently <50 ng/dL (14-30 range), confirming continued androgen suppression 1
- Stable hematologic parameters: Normal WBC (7.7) and platelets (277) without cytopenias that would suggest marrow infiltration
PSA Kinetics Context
The PSA trajectory requires nuanced interpretation:
- Substantial initial decline: Peak 25.38 → nadir 13.06 ng/mL represents 49% reduction, demonstrating drug activity
- Recent increase is modest in absolute terms: 13.06 → 15.60 ng/mL (2.54 ng/mL rise)
- Single data point: One elevated value does not establish a confirmed rising trend per PCWG2 criteria, which require PSA >2 ng/mL above nadir with ≥25% increase confirmed by second measurement ≥3 weeks later 1, 2
Molecular Profile and Resistance Risk
High-Risk Genomic Features
The patient's tumor harbors multiple alterations associated with aggressive biology and treatment resistance:
- AR amplification (9.8-fold): Strongly predicts resistance to AR-targeted therapies including novel agents 3, 4
- TP53 rearrangement: Associated with poor prognosis and potential lineage plasticity 4, 5
- CHEK2 alteration: May confer DNA repair deficiency, though not a canonical HRR gene 4
These genomic features create inherent vulnerability to resistance development, particularly given extensive prior AR pathway exposure (orchiectomy + 8-9 years abiraterone + investigational AR degrader).
Cross-Resistance Considerations
The patient's treatment history creates substantial concern for AR pathway exhaustion:
- Prolonged abiraterone exposure (8-9 years) likely selected for AR-independent mechanisms 3, 4
- Post-Pluvicto progression with new/increased bone lesions despite relatively low PSMA uptake suggests heterogeneous disease biology 4, 5
- AR amplification mechanistically predicts limited durability of any AR-targeted approach 4, 5
Recommended Management Algorithm
Immediate Actions (Next 2-4 Weeks)
Confirm PSA trend: Repeat PSA in 2-3 weeks to determine if rise represents true biochemical progression versus laboratory/biological variation 1
Assess clinical status: Document performance status, pain scores, analgesic requirements, and any new symptoms suggesting progression 2, 6, 2
Continue BMS-986460: Maintain current therapy pending confirmatory PSA and clinical assessment, as single PSA elevation with favorable laboratory parameters does not mandate immediate treatment change 1
Decision Points Based on Confirmatory Testing
If PSA continues rising (≥25% increase confirmed):
- Obtain restaging imaging: PSMA PET/CT to assess for radiographic progression, new lesions, or visceral disease development 1, 4
- Consider mechanism switch: Given extensive AR pathway exposure and AR amplification, prioritize non-AR-targeted options 4, 5:
- Cabazitaxel (preferred if good performance status, adequate bone marrow reserve): Demonstrated OS benefit post-docetaxel and post-ARPI with HR 0.64 2, 6, 4
- 177Lu-PSMA-617: If PSMA-avid disease on imaging, though prior Pluvicto exposure and "relatively low PSMA uptake" may limit efficacy 4, 5
- Clinical trial: Novel agents targeting AR-independent pathways given molecular profile 4
If PSA stabilizes or declines:
- Continue BMS-986460 with monthly PSA monitoring
- Maintain vigilance for delayed resistance emergence given AR amplification
- Plan for eventual progression: Pre-emptively discuss sequencing strategy and clinical trial options
Critical Monitoring Parameters
Monthly assessments:
- PSA (confirm trend with ≥2 measurements)
- CBC with differential (watch for cytopenias suggesting marrow compromise)
- Comprehensive metabolic panel including LDH
- Symptom assessment and performance status
Red flags mandating immediate imaging/treatment change:
- PSA doubling time <3 months
- New pain requiring opioid escalation
- Declining hemoglobin despite stable disease elsewhere
- Rising LDH (>ULN suggests aggressive biology) 1
- Constitutional symptoms (fatigue, weight loss)
Pitfalls to Avoid
Premature treatment abandonment: Single PSA rise with otherwise favorable parameters does not confirm resistance 1
Sequential AR-targeted therapy: Given AR amplification and extensive prior AR pathway exposure, switching to another ARPI (enzalutamide, apalutamide) would likely yield minimal benefit due to cross-resistance 4, 7, 5
Delayed imaging at true progression: Once confirmed PSA progression occurs, radiographic assessment is essential to guide optimal next therapy 1, 4
Ignoring bone marrow reserve: Prior Pluvicto and potential future radioligand therapy require preserved hematologic function; monitor CBC closely 4, 8
Missing HRR testing implications: While CHEK2 alteration noted, confirm whether BRCA1/2 or other canonical HRR genes are altered, as this would prioritize PARP inhibitor combinations if not previously tested 4, 9
Prognosis and Expectations
Current status: The patient demonstrates ongoing disease control with investigational therapy despite heavily pretreated mCRPC. The improving hemoglobin, stable LDH, and maintained castrate state suggest absence of aggressive progression.
Anticipated trajectory: Given AR amplification and extensive AR pathway exposure, durability of any AR-targeted approach (including BMS-986460) is inherently limited 4, 5. Median time to progression with sequential AR therapies in this context is typically 3-6 months 7, 5.
Optimal outcome: Confirming PSA stabilization would support continuing current therapy while preparing for eventual mechanism-based switch to taxane chemotherapy or radioligand therapy, maximizing exposure to multiple life-prolonging mechanisms 4, 5.